Yamauchi, Reika
Ito, Takanori
Yoshio, Sachiyo http://orcid.org/0000-0001-7860-6916
Yamamoto, Takafumi
Mizuno, Kazuyuki
Ishigami, Masatoshi
Kawashima, Hiroki
Yasuda, Satoshi
Shimose, Shigeo
Iwamoto, Hideki
Yamazoe, Taiji
Mori, Taizo
Kakazu, Eiji
Kawaguchi, Takumi
Toyoda, Hidenori
Kanto, Tatsuya
Funding for this research was provided by:
AMED (22fk0210110, 22fk0210094)
Grants-in-Aid for Scientific Research (21K08020)
Article History
Received: 26 December 2022
Accepted: 18 March 2023
First Online: 30 March 2023
Declarations
:
: Takanori Ito received speaker’s fees from Chugai Pharmaceutical Co., Ltd. Masatoshi Ishigami received grants from Chugai Pharmaceutical Co., Ltd. Hidenori Toyoda received speaker’s fees from AbbVie, Bayer, Gilead, Terumo, and Eisai. Takumi Kawaguchi received speaker’s fees from Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Taisho Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and EA Pharma Co., Ltd., Tatsuya Kanto received speaker’s fees from AbbVie and Gilead Sciences. All other authors have no conflict to disclose.
: The study protocol was approved by the ethics committees of the National Center for Global Health and Medicine (NCGM-G-003440–00, NCGM-G-004124–00), Nagoya University (2020–0373), and Kurume University (18246, 19055).
: Informed consent was obtained from the subjects.